Results 71 to 80 of about 18,252,794 (250)

Clinical Diagnosis and Treatment Recommendation of Immune-related Adverse Renal Events Related to Immune Checkpoint Inhibitor

open access: yesChinese Journal of Lung Cancer, 2019
Immune checkpoint inhibitors (ICIs) have been used more and more Increasingly in clinical oncology treatment, which has significantly improved the prognosis of cancer patients.
Wei QIU   +6 more
doaj   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

open access: yesMolecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary   +1 more
wiley   +1 more source

Treatment-related adverse events occurring in ≥1% of the total population (SS).

open access: yes, 2018
Treatment-related adverse events occurring in ≥1% of the total population (SS).
Lionel Noah (6095636)   +7 more
core   +1 more source

Toward Personalized Response Monitoring in Melanoma Patients Treated with Immunotherapy and Target Therapy

open access: yesDiagnostics
Background/Objectives: Immunotherapy and targeted therapy have revolutionized the treatment of advanced cutaneous melanoma. However, predicting individual response and managing resistance remain major challenges.
Federico Venturi   +13 more
doaj   +1 more source

Adverse events associated with acupuncture: three multicentre randomized controlled trials of 1968 cases in China

open access: yesTrials, 2011
Background In order to evaluate the safety of acupuncture in China objectively, we investigated the adverse events associated with acupuncture based on three multicentre randomized controlled trials (RCTs) to assess the safety of acupuncture, identifying
Zheng Hui   +6 more
doaj   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

open access: yesMolecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura   +19 more
wiley   +1 more source

A structural equation model of adverse events and length of stay in hospitals [PDF]

open access: yes
Adverse events in hospitals cause significant morbidity and mortality, and considerable effort has been invested into analysing their incidence and preventability. An unresolved issue in models of medical adverse events is potential endogeneity of length
Katharina Hauck, Xueyan Zhao
core  

Treatment-related adverse events.

open access: yes, 2015
Abbreviations: Hb, hemoglobin; ANC, absolute neutrophil counta Influenza-like symptoms: pyrexia, rigors, headache, and myalgiab Gastrointestinal symptoms: anorexia, nausea, and vomitingc Dermatologic symptoms: dermatitis, pruritus, and alopeciad ...
Xiaoqiong Shao (819166)   +21 more
core   +1 more source

Preoperative circulating tumor cells integrated with imaging analysis for prognostic evaluation in head and neck squamous cell carcinoma

open access: yesMolecular Oncology, EarlyView.
Detecting circulating tumor cells (CTCs) in blood before surgery may help predict outcomes in patients with head and neck squamous cell carcinoma (HNSCC). Here, we show when combined with tumor size and lymph node involvement from routine imaging, CTC status identifies high‐risk patients with poorer survival—offering a simple, minimally invasive tool ...
Susanne Flach   +9 more
wiley   +1 more source

Descriptive summary of treatment-related adverse events.

open access: yes, 2016
Descriptive summary of treatment-related adverse events.
Zhifeng Li (1776799)   +6 more
core   +1 more source

Home - About - Disclaimer - Privacy